STOCKHOLM--(BUSINESS WIRE)--Regulatory News:
During April 25-27, RaySearch Laboratories AB (publ)(STO:RAYB) will be exhibiting at the 3rd ESTRO Forum in Barcelona, Spain. The company will demonstrate the new features in its proprietary treatment planning system RayStation®, notably new advanced proton functionalities and planning tools for Wave arc capable machines. Attendees are welcome to stop by RaySearch in booth #2200 and demonstrations can already now be booked at raysearchlabs.com.
About RayStation®
RayStation® integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as Multi-Criteria Optimization with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron and proton therapy. The system is built on the latest software architecture and has a graphical user interface offering state-of-the-art usability.
Highlights in RayStation 4.7
Multi-Criteria Optimization for PBS RayStation® 4.7 features Multi-Criteria Optimization (MCO) for proton pencil beam scanning (PBS) optimization. MCO planning makes it possible to plan in a more interactive and exploratory way where fundamental trade-offs can be made in real time by the dosimetrist and the physician. It can help simplify the planning process while improving the quality of the plans. This has previously been available for photon treatments, and is now also available for proton PBS planning.
Planning for Wave Arc Capable Machines (Brainlab Vero)
In 2013, RaySearch and Brainlab AG have agreed to collaborate in the field of treatment planning for radiation therapy and dose optimization with the goal to automate crucial steps in the treatment process. As a result of this collaboration the Wave arc planning module is now available in RayStation® 4.7. With Wave arc planning, it is now possible to plan VMAT treatments for Brainlab’s Vero machine, where the gantry ring is allowed to turn at the same time as the gantry angle changes. This allows for design of even more patient individualized treatments.
Works in Progress
The results of ongoing developments will be demonstrated, including carbon ion planning, improved plan protocols for automated planning, and general system improvements.
Lunch Symposium: Advancing Radiation Therapy through Software Innovation
On Sunday April 26, from 13:15 to 14:30, RaySearch will hold a lunch symposium on the theme of “Advancing Radiation Therapy through Software Innovation” in meeting room #115, Level 1. The symposium will show how software is and will be the driving force of innovation in radiation therapy and notably in adaptive therapy.
Moderator: Prof. Dr. Hans Langendijk, Chair. Department of Radiation Oncology, Groningen, Netherlands
Considerations for implementing adaptive therapy using RayStation®,
Bon Mzenda, Chief Physicist, Auckland Radiation Oncology, Auckland, New Zealand
Breaking the myth of the single vendor
Hsiao-Ming Lu, Director of Clinical Physics, Massachusetts General Hospital, Harvard Medical School, Boston, USA
Advancing radiation therapy through software innovation
Johan Löf, CEO, RaySearch Laboratories AB, Stockholm, Sweden
About RaySearch
RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch markets the RayStation® treatment planning system to cancer centers all over the world. In addition, RaySearch’s products are distributed through licensing agreements with leading medical technology companies such as Philips, Nucletron, IBA, Varian and Brainlab. To date, 15 products have been launched via partners and RaySearch’s software is used by over 2,500 clinics in more than 65 countries. RaySearch was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the company is listed on Nasdaq OMX Nordic.
For more information about RaySearch, visit www.raysearchlabs.com
This information was brought to you by Cision http://news.cision.com